trending Market Intelligence /marketintelligence/en/news-insights/trending/qfraVNSyakY_-obbEcb70A2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Avadel hospital drug's review period extended by US FDA

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Avadel hospital drug's review period extended by US FDA

Avadel Pharmaceuticals PLC said the U.S. Food and Drug Administration has extended the review period of AV001 by three months.

The FDA accepted the new drug application for Avadel's hospital product candidate in May and granted it a priority review.

The Dublin-based company said it submitted additional information regarding the application in response to the regulator's request. The FDA categorized these submissions as a major amendment and will decide on Avadel's new drug application by Dec. 15.

Avadel CEO Greg Divis said if AV001 is approved, the extension will not impact the timeline for the U.S. launch, which is expected in the first quarter of 2020.

The pharmaceutical company did not disclose the indication for the product.

Avadel's share price was down 8.64% to $2.01 after market close Aug. 8.